Day One Biopharmaceuticals, Inc. (DAWN)
USD 12.53
(-0.87%)
USD 12.53
(-0.87%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | 383 Thousand | 531 Thousand | 199 Thousand | 155 Thousand | - |
| Gross Profit | -383 Thousand | -531 Thousand | -199 Thousand | -155 Thousand | - |
| Operating Expenses | 206.06 Million | 146.9 Million | 72.74 Million | 13.78 Million | 14.9 Million |
| Selling, General and Administrative Expenses | 75.54 Million | 61.29 Million | 29.15 Million | 4.68 Million | 1 Million |
| Research and Development Expenses | 130.52 Million | 85.61 Million | 43.58 Million | 9.1 Million | 13.89 Million |
| Other Expenses | 1.00 | -18 Thousand | -15 Thousand | -31 Thousand | -2000.00 |
| Cost and Expenses | 206.06 Million | 146.9 Million | 72.74 Million | 13.78 Million | 14.9 Million |
| Operating Income | -206.06 Million | -146.9 Million | -72.74 Million | -13.78 Million | -14.9 Million |
| Interest Expense | - | 4.74 Million | 4000.00 | 30 Thousand | 2.07 Million |
| Income Tax Expense | - | -10 Million | -2.31 Million | -3.33 Million | -2.27 Million |
| Earnings before Tax | -188.91 Million | -142.18 Million | -72.75 Million | -43.84 Million | -16.98 Million |
| Net Income | -188.91 Million | -132.17 Million | -70.44 Million | -40.5 Million | -14.71 Million |
| Earnings Per Share Basic | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| Earnings Per Share Diluted | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| Weighted Average Shares Outstanding | 79.77 Million | 65.46 Million | 61.95 Million | 61.92 Million | 61.92 Million |
| Weighted Average Shares Outstanding (Diluted) | 79.77 Million | 65.46 Million | 61.95 Million | 61.92 Million | 61.92 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -206.06 Million | -141.65 Million | -72.55 Million | -43.65 Million | -2000.00 |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 20.07 Million | 8.19 Million | - | - | 560 Thousand | - |
| Cost of Revenue | 1.59 Million | 707 Thousand | 116 Thousand | 383 Thousand | 280 Thousand | 99 Thousand |
| Gross Profit | 18.48 Million | 7.48 Million | -116 Thousand | -383 Thousand | 280 Thousand | -99 Thousand |
| Operating Expenses | 62.53 Million | 122.29 Million | 66.65 Million | 205.68 Million | 59.51 Million | 51.43 Million |
| Selling, General and Administrative Expenses | 28.97 Million | 30.18 Million | 26.44 Million | - | 22.16 Million | 18.27 Million |
| Research and Development Expenses | 33.56 Million | 92.1 Million | 40.21 Million | - | 37.34 Million | 33.16 Million |
| Other Expenses | - | 107.99 Million | -10 Thousand | - | -18 Thousand | -3000.00 |
| Cost and Expenses | 64.12 Million | 122.99 Million | 66.76 Million | 206.06 Million | 59.51 Million | 51.43 Million |
| Operating Income | 29.63 Million | -114.8 Million | -66.76 Million | -206.06 Million | -59.51 Million | -51.43 Million |
| Interest Expense | - | - | - | - | 3.46 Million | - |
| Income Tax Expense | 882 Thousand | 1.55 Million | 72.72 Thousand | - | 10.52 Million | -99 Thousand |
| Earnings before Tax | 36.15 Million | -2.85 Million | -62.41 Million | -188.91 Million | -54.51 Million | -46.15 Million |
| Net Income | 37.03 Million | -4.4 Million | -62.41 Million | -188.91 Million | -54.51 Million | -46.15 Million |
| Earnings Per Share Basic | 0.38 | -0.05 | -0.72 | - | -0.62 | -0.54 |
| Earnings Per Share Diluted | 0.38 | -0.05 | -0.72 | - | -0.62 | -0.54 |
| Weighted Average Shares Outstanding | 97.46 Million | 87.12 Million | 86.67 Million | 79.77 Million | 87.22 Million | 85.95 Million |
| Weighted Average Shares Outstanding (Diluted) | 97.46 Million | 87.12 Million | 86.67 Million | 79.77 Million | 87.22 Million | 85.95 Million |
| Gross Margin | 0.92 | 0.91 | - | - | 0.50 | - |
| EBIT Margin | 1.48 | -13.96 | - | - | -115.07 | - |
| Profit Margin | 1.85 | -0.54 | - | - | -97.34 | - |
| EBITDA | 29.63 Million | -114.39 Million | -66.65 Million | - | -64.43 Million | -51.43 Million |
| Earnings Before Tax Margin | 1.48 | -14.01 | - | - | -106.28 | - |
RNK
1780
LPX
BGS
ARYC
BAKK